Cambridge Investment Research Advisors, Inc. Repligen Corp Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Repligen Corp stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 1,681 shares of RGEN stock, worth $235,373. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,681
Previous 1,971
14.71%
Holding current value
$235,373
Previous $293,000
17.41%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding RGEN
# of Institutions
482Shares Held
56.3MCall Options Held
251KPut Options Held
458K-
Black Rock Inc. New York, NY7.57MShares$1.06 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.14MShares$999 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$714 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$237 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.54MShares$216 Million1.48% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.77B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....